BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 11174383)

  • 1. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
    Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
    J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
    Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
    Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma.
    Chiarion-Sileni V; Bononi A; Fornasa CV; Soraru M; Alaibac M; Ferrazzi E; Redelotti R; Peserico A; Monfardini S; Salvagno L
    Cancer; 2002 Aug; 95(3):569-75. PubMed ID: 12209749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.
    Stadler R; Otte HG; Luger T; Henz BM; Kühl P; Zwingers T; Sterry W
    Blood; 1998 Nov; 92(10):3578-81. PubMed ID: 9808550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP; Levitan D; Fleischer AB
    J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy.
    Stadler R; Otte HG
    Recent Results Cancer Res; 1995; 139():391-401. PubMed ID: 7597306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
    J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
    Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
    J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group.
    Rupoli S; Barulli S; Guiducci B; Offidani M; Mozzicafreddo G; Simonacci M; Filosa G; Giacchetti A; Ricotti G; Brandozzi G; Cataldi I; Serresi S; Ceschini R; Bugatti L; Offidani A; Giangiacomi M; Brancorsini D; Leoni P
    Haematologica; 1999 Sep; 84(9):809-13. PubMed ID: 10477454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy.
    Wollina U; Liebold K; Kaatz M; Looks A; Stuhlert A; Lange D
    Oncol Rep; 2000; 7(6):1197-201. PubMed ID: 11032913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
    Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
    Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
    Straus DJ; Duvic M; Kuzel T; Horwitz S; Demierre MF; Myskowski P; Steckel S
    Cancer; 2007 May; 109(9):1799-803. PubMed ID: 17366595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination therapy with interferon alfa 2a and PUVA in cutaneous T-cell lymphoma].
    Otte HG; Herges A; Stadler R
    Hautarzt; 1992 Nov; 43(11):695-9. PubMed ID: 1468931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
    Quaglino P; Knobler R; Fierro MT; Savoia P; Marra E; Fava P; Bernengo MG
    Int J Dermatol; 2013 Nov; 52(11):1308-18. PubMed ID: 23786842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
    Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
    J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial.
    Vieyra-Garcia P; Fink-Puches R; Porkert S; Lang R; Pöchlauer S; Ratzinger G; Tanew A; Selhofer S; Paul-Gunther S; Hofer A; Gruber-Wackernagel A; Legat F; Patra V; Quehenberger F; Cerroni L; Clark R; Wolf P
    JAMA Dermatol; 2019 May; 155(5):538-547. PubMed ID: 30892603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
    Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
    Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
    Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
    Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interferon-alpha and PUVA therapy for mycosis fungoides].
    Marschalkó M; Kovács J; Somlai B; Berecz M; Hídvégi B; Hársing J; Désaknai M; Horváth A
    Orv Hetil; 2001 Sep; 142(37):2021-3. PubMed ID: 11582733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.